StiL Forschungs-GmbH

StiL Forschungs-GmbH is a specialized clinical research organization based in Giessen, Germany, serving as the operational entity for the Studiengruppe indolente Lymphome (StiL). The group is a leading academic research network dedicated to improving the treatment of indolent lymphomas and mantle cell lymphoma through large-scale, multicenter clinical trials. StiL is best known for its pivotal Phase 3 trials that have redefined international treatment standards, particularly the demonstration of bendamustine plus rituximab as a superior and less toxic alternative to standard CHOP-R therapy. The organization manages all aspects of trial coordination, data management, and regulatory compliance for its extensive network of participating oncology centers. By collaborating with over 160 hospitals and private practices across Germany, StiL Forschungs-GmbH facilitates high-quality clinical research that directly impacts patient care in hematologic oncology.